Format

Send to

Choose Destination

Infliximab for refractory sarcoidosis.

Author information

1
Department of Internal Medicine, University of Cincinnati Medical Center, OH, USA. bob.baughman@uc.edu

Erratum in

  • Sarcoidosis Vasc Diffuse Lung Dis 2001 Oct;18(3):310.

Abstract

BACKGROUND AND AIM OF WORK:

Tumor necrosis factor-alpha (TNF-alpha) appears to be an important cytokine in the inflammation of sarcoidosis. Infliximab is a chimeric monoclonal antibody which specifically inhibits TNF-alpha. We investigated the efficacy of infliximab for the therapy of chronic, resistant sarcoidosis.

METHODS:

Patients with persistent symptomatic sarcoidosis despite corticosteroids and immunosuppressive agents were selected for treatment with infliximab. Patients were treated initially and at 2, 4, and 12 weeks with 5 mg/kg of infliximab at each treatment. Index lesions, which had progressed despite corticosteroid therapy, were reevaluated at 16 weeks.

RESULTS:

Three patients were treated. In two patients, the index lesion was lupus pernio, which significantly improved with infliximab. The third patient had restrictive lung disease. At week 16, there was a 26% improvement in the vital capacity from pretreatment values. All patients tolerated the treatments well.

CONCLUSIONS:

Infliximab was associated with significant improvement in chronic sarcoidosis.

PMID:
11354550
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center